Picture1.1.png
BCNN TEKUMO ANNOUNCES Q3 PRELIMINARY RESULTS
October 18, 2023 09:30 ET | Balincan USA, Inc.
NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Balincan USA Inc. ("Balincan" or the "Company") and Tekumo announces preliminary results for the third quarter. Revenue for the third quarter...
Logo_Anaqua-Color.png
Anaqua Builds on its Momentum in Japan with New Leadership, Clients, Solutions and Country HQ
September 26, 2023 03:00 ET | Anaqua
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Anaqua, the leading global innovation and intellectual property (IP) management technology provider, today announced changes to its executive leadership...
The Human Rights and
The Human Rights and Rights to Religious Freedom of 600,000 Japanese Citizens are at Risk
September 21, 2023 20:02 ET | Center for Studies on New Religions, "Bitter Winter"
Washington, DC, Sept. 21, 2023 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE   Center for Studies on New Religions,  Human Rights and Religious Freedom Experts Decry Government Persecution of...
Inventiva et Hepalys
Inventiva et Hepalys Pharma, Inc., signent un accord de licence exclusif pour développer et commercialiser lanifibranor au Japon et en Corée du Sud
September 20, 2023 16:00 ET | INVENTIVA
Hepalys Pharma, Inc. est une nouvelle société créée par Catalys Pacific, et dans laquelle Inventiva détient une participation de 30%. Dans le cadre de l’accord de licence exclusif, Inventiva...
Inventiva and Hepaly
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
September 20, 2023 16:00 ET | INVENTIVA
Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position.  Under the exclusive licensing agreement, Inventiva will receive a $10 million...
The Human Rights and
The Human Rights and Rights to Religious Freedom of 600,000 Japanese Citizens are at Risk
September 19, 2023 22:04 ET | Center for Studies on New Religions, "Bitter Winter"
Washington, DC, Sept. 19, 2023 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE   Center for Studies on New Religions,  Human Rights and Religious Freedom Experts Decry Government Persecution of...
The Human Rights and
The Human Rights and Rights to Religious Freedom of 600,000 Japanese Citizens are at Risk
September 19, 2023 14:07 ET | Center for Studies on New Religions, "Bitter Winter"
Washington, DC, Sept. 19, 2023 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE   Center for Studies on New Religions,  Human Rights and Religious Freedom Experts Decry Government Persecution of...
ClimateAi Logo Black (1).png
ClimateAi Announces Expanded Presence in Japan to Advance Climate Resilience Solutions
September 14, 2023 07:00 ET | ClimateAi
SAN FRANCISCO, Sept. 14, 2023 (GLOBE NEWSWIRE) -- ClimateAi, one of the fastest-growing climate resilience software service providers, today announced the expansion of its presence in Japan with a...
Salipro_logo_2lines.png
サリプロ・バイオテック (Salipro Biotech)、住友ファーマと研究提携を締結し、創薬プログラムを推進
September 12, 2023 02:00 ET | Salipro Biotech AB
本提携では、サリプロ・バイオテックの独自の専門知識とSalipro®プラットフォーム技術を活用して困難な薬物標的を安定化し、住友ファーマの創薬プログラムによる化合物の薬理学的特性を研究 する。 スウェーデン・ストックホルム発, Sept. 12, 2023 (GLOBE NEWSWIRE) -- スウェーデンのバイオテクノロジー企業であるサリプロ・バイオテックAB (Salipro...
Salipro_logo_2lines.png
Salipro Biotech enters into research collaboration with Sumitomo Pharma to advance a drug discovery program
September 12, 2023 02:00 ET | Salipro Biotech AB
The collaboration leverages Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilize a challenging drug target to investigate the pharmacological characteristics of a...